Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00519142 · ClinicalTrials.gov registry record · Phase 3
Mitiglinide in Combination With Metformin vs. Metformin Alone in Patients With Type 2 Diabetes Mellitus
A Phase 3 study of Diabetes Mellitus, Type 2, sponsored by Elixir Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 367
- Enrollment target
- 20
- Study locations
NCT00519142 is a Phase 3 study of Diabetes Mellitus, Type 2 that has completed, run by Elixir Pharmaceuticals. The registered enrollment target is 367 participants, below the 4,484-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (92% lower). The trial reports 20 study locations across 6 states.
The verdict
NCT00519142, a Phase 3 study of Diabetes Mellitus, Type 2, has completed, sponsored by Elixir Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 367 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this study is to demonstrate whether mitiglinide administered in combination with metformin is more effective than metformin alone in patients with Type 2 diabetes mellitus (T2DM) whose blood sugar is not well controlled taking metformin alone. This is a 24 week study which measures improvement in blood sugar after of treatment.
Conditions Studied
Interventions
- DRUG placebo for mitiglinide
- DRUG mitiglinide
Study Locations (20)
California
- Elixir Study Site - Greenbrae
- Elixir Study Site - La Jolla
- Elixir Study Site - Los Angeles
- Elixir Study Site - Los Gatos
- Elixir Study Site(s) - Oakland Area
- Elixir Study Site - Orange
- Elixir Study Site - West Hills
- Elixir Study Site - Westlake Village
Florida
- Elixir Study Site - Chiefland
- Elixir Study Site - Coral Gables
- Elixir Study Site - Kissimmee
- Elixir Study Site(s) - Miami
- Elixir Study Site - Saint Cloud
- Elixir Study Site - Winter Park
Georgia
- Elixir Study Site - Atlanta
- Elixir Study Site - Austell
- Elixir Study Site - Perry
Arizona
- Elixir Study Site - Glendale
Colorado
- Elixir Study Site - Pueblo
District of Columbia
- Elixir Study Site(s) - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 367 participants |
| Start Date | 2007-08 |
| Est. Completion | 2008-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00519142
The ClinicalTrials.gov registry entry for NCT00519142 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 367 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,484-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (92% lower). The listed sponsor is Elixir Pharmaceuticals, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 2 interventions - of which placebo for mitiglinide is the first listed.
NCT00519142 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT00519142 about?
NCT00519142 is a clinical study titled "Mitiglinide in Combination With Metformin vs. Metformin Alone in Patients With Type 2 Diabetes Mellitus". The primary objective of this study is to demonstrate whether mitiglinide administered in combination with metformin is more effective than metformin alone in patients with Type 2 diabetes mellitus (T2DM) whose blood sugar is not well controlled taking metformin alone. This is a 24 week study which ...
What is the current status of trial NCT00519142?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 367 participants. The study started on 2007-08. Estimated completion is 2008-10.
What conditions does trial NCT00519142 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2.
What interventions are being tested in trial NCT00519142?
The interventions under investigation include: placebo for mitiglinide (DRUG), mitiglinide (DRUG).
Who is sponsoring clinical trial NCT00519142?
This trial is sponsored by Elixir Pharmaceuticals, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00519142 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
RECRUITING · Phase 3
-
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
ACTIVE NOT RECRUITING · Phase 3
-
A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes
ACTIVE NOT RECRUITING · Phase 3
-
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight
ACTIVE NOT RECRUITING · Phase 3
-
A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial)
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.